Augmented efficacy with the combination of blockade of the NOTCH-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model

[1]  A. Gurney,et al.  Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts , 2014, Leukemia.

[2]  Xin Lu,et al.  Jagged1 contributes to the drug resistance of Jurkat cells in contact with human umbilical cord-derived mesenchymal stem cells , 2013, Oncology letters.

[3]  B. Dörken,et al.  Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed–Sternberg cells , 2012, Leukemia.

[4]  R. Johnstone,et al.  A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. , 2011, Blood.

[5]  Ming Li,et al.  Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma , 2011, Cellular Oncology.

[6]  G. Pizzolo,et al.  Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. , 2011, Blood.

[7]  S. Steinberg,et al.  Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. , 2011, Blood.

[8]  E. Petricoin,et al.  NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols , 2010, Leukemia.

[9]  Olivier Hermine,et al.  Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1–associated adult T-cell leukemia , 2010, Proceedings of the National Academy of Sciences.

[10]  Y. Furukawa,et al.  Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. , 2010, Blood.

[11]  Richard S Larson,et al.  Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. , 2010, Blood.

[12]  V. Seshan,et al.  Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma , 2010, Clinical Cancer Research.

[13]  J. Aster,et al.  Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. , 2008, The Journal of clinical investigation.

[14]  P. Dent,et al.  Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells , 2008, Clinical Cancer Research.

[15]  Govind Bhagat,et al.  Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia , 2007, Nature Medicine.

[16]  B. Clurman,et al.  FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors , 2007, The Journal of experimental medicine.

[17]  A. Ferrando,et al.  The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia , 2007, The Journal of experimental medicine.

[18]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[19]  A. Look,et al.  Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia , 2006, Nature Reviews Cancer.

[20]  Rhett A. Kovall,et al.  Crystal Structure of the CSL-Notch-Mastermind Ternary Complex Bound to DNA , 2006, Cell.

[21]  I. Screpanti,et al.  Notch3 and pre‐TCR interaction unveils distinct NF‐κB pathways in T‐cell development and leukemia , 2006, The EMBO journal.

[22]  W. Pear,et al.  The Notch ‘gospel’ , 2005, EMBO reports.

[23]  Q. Su,et al.  Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. , 2005, Cancer research.

[24]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[25]  M. Matsuoka,et al.  Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro , 2004, Leukemia.

[26]  N. Mori,et al.  Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. , 2004, Neoplasia.

[27]  M. Tomonaga,et al.  Apoptosis Induced by the Histone Deacetylase Inhibitor FR901228 in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines and Primary Adult T-Cell Leukemia Cells , 2004, Journal of Virology.

[28]  D. Selkoe,et al.  The Notch Ligands, Jagged and Delta, Are Sequentially Processed by α-Secretase and Presenilin/γ-Secretase and Release Signaling Fragments* , 2003, Journal of Biological Chemistry.

[29]  Christin E Bland,et al.  Notch-induced Proteolysis and Nuclear Localization of the Delta Ligand* , 2003, The Journal of Biological Chemistry.

[30]  H. Stein,et al.  Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. , 2002, Blood.

[31]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[32]  L. Ratner,et al.  The contribution of NF-kappa B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. , 2001, Blood.

[33]  M. Tomonaga,et al.  A new G‐CSF‐supported combination chemotherapy, LSG15, for adult T‐cell leukaemia‐lymphoma: Japan Clinical Oncology Group Study 9303 , 2001, British journal of haematology.

[34]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[35]  U. Lendahl,et al.  Constitutive activation of NF‐κB and T‐cell leukemia/lymphoma in Notch3 transgenic mice , 2000, The EMBO journal.

[36]  A. Parks,et al.  Ligand endocytosis drives receptor dissociation and activation in the Notch pathway. , 2000, Development.

[37]  J. Laborda,et al.  T cell leukemia-associated human Notch/translocation-associated Notch homologue has I kappa B-like activity and physically interacts with nuclear factor-kappa B proteins in T cells , 1996, The Journal of experimental medicine.

[38]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.

[39]  John D. Minna,et al.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma , 1980, Proceedings of the National Academy of Sciences.

[40]  T. Golde,et al.  Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. , 2008, Laboratory investigation; a journal of technical methods and pathology.

[41]  T. Golde,et al.  Off the beaten pathway: the complex cross talk between Notch and NF-κB , 2008, Laboratory Investigation.

[42]  Malay Mandal,et al.  Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. , 2007, Nature medicine.

[43]  R. Horie.  NF-kappaB in pathogenesis and treatment of adult T-cell leukemia/lymphoma. , 2007, International reviews of immunology.

[44]  Malay Mandal,et al.  Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia , 2007, Nature Medicine.

[45]  K. Jeang,et al.  Modulation of nuclear factor-ϰB by human T cell leukemia virus type 1 tax protein , 2006, Immunologic research.

[46]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[47]  Michael Karin,et al.  NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.

[48]  F. Oswald,et al.  NF- k B2 Is a Putative Target Gene of Activated Notch-1 via RBP-J k , 1998 .

[49]  H. Towler,et al.  Adult T-cell leukemia : antigen in an ATL cell line and detection of antibodies to the antigen in human sera , 2022 .